Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Radiology ; 310(3): e231557, 2024 03.
Article in English | MEDLINE | ID: mdl-38441097

ABSTRACT

Background Coronary artery calcium (CAC) has prognostic value for major adverse cardiovascular events (MACE) in asymptomatic individuals, whereas its role in symptomatic patients is less clear. Purpose To assess the prognostic value of CAC scoring for MACE in participants with stable chest pain initially referred for invasive coronary angiography (ICA). Materials and Methods This prespecified subgroup analysis from the Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) trial, conducted between October 2015 and April 2019 across 26 centers in 16 countries, focused on adult patients with stable chest pain referred for ICA. Participants were randomly assigned to undergo either ICA or coronary CT. CAC scores from noncontrast CT scans were categorized into low, intermediate, and high groups based on scores of 0, 1-399, and 400 or higher, respectively. The end point of the study was the occurrence of MACE (myocardial infarction, stroke, and cardiovascular death) over a median 3.5-year follow-up, analyzed using Cox proportional hazard regression tests. Results The study involved 1749 participants (mean age, 60 years ± 10 [SD]; 992 female). The prevalence of obstructive coronary artery disease (CAD) at CT angiography rose from 4.1% (95% CI: 2.8, 5.8) in the CAC score 0 group to 76.1% (95% CI: 70.3, 81.2) in the CAC score 400 or higher group. Revascularization rates increased from 1.7% to 46.2% across the same groups (P < .001). The CAC score 0 group had a lower MACE risk (0.5%; HR, 0.08 [95% CI: 0.02, 0.30]; P < .001), as did the 1-399 CAC score group (1.9%; HR, 0.27 [95% CI: 0.13, 0.59]; P = .001), compared with the 400 or higher CAC score group (6.8%). No significant difference in MACE between sexes was observed (P = .68). Conclusion In participants with stable chest pain initially referred for ICA, a CAC score of 0 showed very low risk of MACE, and higher CAC scores showed increasing risk of obstructive CAD, revascularization, and MACE at follow-up. Clinical trial registration no. NCT02400229 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Hanneman and Gulsin in this issue.


Subject(s)
Coronary Artery Disease , Myocardial Infarction , Adult , Humans , Female , Middle Aged , Calcium , Coronary Artery Disease/diagnostic imaging , Chest Pain/diagnostic imaging
2.
J Clin Lipidol ; 10(4): 996-1003, 2016.
Article in English | MEDLINE | ID: mdl-27578132

ABSTRACT

BACKGROUND: The metabolic syndrome (MetS) is highly prevalent and associated with an increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle recommendations to treat MetS often include the replacement of saturated fats (SFAs) and monosaccharides with unsaturated fat. However, it is unclear whether metabolic parameters will improve more when the saturated fat in American Heart Association (AHA) diets is replaced with higher concentrations of monounsaturated or polyunsaturated fatty acids (MUFA or PUFA). OBJECTIVE: To test the hypothesis that an AHA diet enriched in MUFA improves lipoprotein lipids, insulin resistance, inflammation, and endothelial function to a greater extent than a diet enriched in PUFA in middle-aged men and women with MetS. METHODS: A prospective, open-label, parallel group design with randomization to a hypocaloric MUFA or PUFA-enriched diet after weight stabilization on an AHA step I diet. Participants consumed 3 MUFA-enriched or PUFA-enriched muffins daily with additional supplementation as required to ensure 25%-50% increases in dietary fat intake from these sources at the expense of SFA and the opposing unsaturated fat. Changes in MetS components were measured at baseline and after 6 months of dietary intervention. RESULTS: Thirty-nine participants (mean age, 60.8 years; 79% African-American, 60% women) with MetS completed the 6-month study. Compared to baseline, assignment to either MUFA (n = 23) or PUFA (n = 16) both were associated with weight loss (MUFA: -2.3 ± 1 kg, P = .06; PUFA: -4.6 ± 2 kg; P = .002), but PUFA was also associated with reductions in triglycerides (TG) (-30 ± 18 mg/dL, P = .02), systolic blood pressure (BP) (-7 ± 3 mm Hg, P = .01), diastolic BP (DBP) (-4 ± 2 mm Hg, P = .01) and improved flow mediated dilation (FMD) (7.1% ± 1.8% vs 13.6% ± 2%, absolute increase; P = .0001). When compared to MUFA treatment, PUFA intervention was associated with reduced TG (P = .04) and DBP (P = .07) as well as increased FMD (P = .04) even after adjustment for changes in weight. There was no effect on total cholesterol, low-density lipoprotein cholesterol, glucose, high-sensitivity C-reactive protein (hs-CRP), or other inflammatory proteins. Overall, 25% (4 of 16) assigned to PUFA and 13% (3 of 23) to MUFA converted to non-MetS status. CONCLUSION: Substitution of SFA with PUFA in patients with MetS is associated with greater reductions in TG and improvement in endothelial function than MUFA that is independent of weight loss. These preliminary findings raise the possibility that PUFA may be the unsaturated fat of choice to reduce cardiometabolic risk in patients with MetS.


Subject(s)
Dietary Fats, Unsaturated/pharmacology , Fatty Acids, Monounsaturated/pharmacology , Fatty Acids, Unsaturated/pharmacology , Metabolic Syndrome/diet therapy , Adult , Aged , Dietary Fats, Unsaturated/therapeutic use , Endothelium, Vascular/drug effects , Endothelium, Vascular/pathology , Fatty Acids, Monounsaturated/therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Female , Humans , Insulin Resistance , Lipoproteins/blood , Male , Metabolic Syndrome/blood , Metabolic Syndrome/complications , Metabolic Syndrome/pathology , Middle Aged , Overweight/complications
3.
J Biomech ; 48(1): 122-9, 2015 Jan 02.
Article in English | MEDLINE | ID: mdl-25468298

ABSTRACT

Surface damage to articular cartilage is recognized as the initial underlying process causing the loss of mechanical function in early-stage osteoarthritis. In this study, we developed structure-modifying treatments to potentially prevent, stabilize or reverse the loss in mechanical function. Various polymers (chondroitin sulfate, carboxymethylcellulose, sodium hyaluronate) and photoinitiators (riboflavin, irgacure 2959) were applied to the surface of collagenase-degraded cartilage and crosslinked in situ using UV light irradiation. While matrix permeability and deformation significantly increased following collagenase-induced degradation of the superficial zone, resurfacing using tyramine-substituted sodium hyaluronate and riboflavin decreased both values to a level comparable to that of intact cartilage. Repetitive loading of resurfaced cartilage showed minimal variation in the mechanical response over a 7 day period. Cartilage resurfaced using a low concentration of riboflavin had viable cells in all zones while a higher concentration resulted in a thin layer of cell death in the uppermost superficial zone. Our approach to repair surface damage initiates a new therapeutic advance in the treatment of injured articular cartilage with potential benefits that include enhanced mechanical properties, reduced susceptibility to enzymatic degradation and reduced adhesion of macrophages.


Subject(s)
Cartilage, Articular/drug effects , Chondroitin Sulfates/therapeutic use , Hyaluronic Acid/therapeutic use , Osteoarthritis/therapy , Riboflavin/therapeutic use , Animals , Carboxymethylcellulose Sodium/pharmacology , Carboxymethylcellulose Sodium/therapeutic use , Cartilage, Articular/radiation effects , Cattle , Cell Death , Cell Survival/drug effects , Cell Survival/radiation effects , Chondrocytes/drug effects , Chondrocytes/radiation effects , Chondroitin Sulfates/pharmacology , Collagenases , Drug Evaluation, Preclinical , Hyaluronic Acid/pharmacology , Propane/analogs & derivatives , Propane/pharmacology , Propane/therapeutic use , Riboflavin/chemistry , Riboflavin/pharmacology , Tyramine/chemistry , Ultraviolet Rays
5.
J Acoust Soc Am ; 126(5): EL128-33, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19894787

ABSTRACT

In music, multiple pitches often occur simultaneously, an essential feature of harmony. In the present study, the authors assessed the ability of cochlear implant (CI) users to perceive polyphonic pitch. Acoustically presented stimuli consisted of one, two, or three superposed tones with different fundamental frequencies (f(0)). The normal hearing control group obtained significantly higher mean scores than the CI group. CI users performed near chance levels in recognizing two- and three-pitch stimuli, and demonstrated perceptual fusion of multiple pitches as single-pitch units. These results suggest that limitations in polyphonic pitch perception may significantly impair music perception in CI users.


Subject(s)
Cochlear Implants , Deafness/therapy , Music , Pitch Discrimination/physiology , Psychoacoustics , Acoustic Stimulation , Adult , Aged , Deafness/physiopathology , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL